HRP20100160T1 - Pripravak koji sadrži roziglitazon i metformin - Google Patents
Pripravak koji sadrži roziglitazon i metformin Download PDFInfo
- Publication number
- HRP20100160T1 HRP20100160T1 HR20100160T HRP20100160T HRP20100160T1 HR P20100160 T1 HRP20100160 T1 HR P20100160T1 HR 20100160 T HR20100160 T HR 20100160T HR P20100160 T HRP20100160 T HR P20100160T HR P20100160 T1 HRP20100160 T1 HR P20100160T1
- Authority
- HR
- Croatia
- Prior art keywords
- dosage form
- oral dosage
- form according
- core
- coating
- Prior art date
Links
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 title claims abstract 11
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract 10
- 229960003105 metformin Drugs 0.000 title claims abstract 10
- 229960004586 rosiglitazone Drugs 0.000 title 1
- 239000006186 oral dosage form Substances 0.000 claims abstract 23
- 239000011248 coating agent Substances 0.000 claims abstract 17
- 238000000576 coating method Methods 0.000 claims abstract 17
- 150000003839 salts Chemical class 0.000 claims abstract 13
- 239000012453 solvate Substances 0.000 claims abstract 12
- 239000000463 material Substances 0.000 claims 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 2
- 102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 claims 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 2
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical class N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Oralni oblik doziranja s erodibilnom jezgrom koja sadrži 5-[4-[2-(N-metil-N-(2-piridil)amino)etoksi]benzil] tiazolidin-2,4-dion, ili njegovu farmaceutski prihvatljivu sol ili solvat, i metformin, ili njegovu farmaceutski prihvatljivu sol ili solvat, gdje navedena jezgra nosi oblogu s jednim ili dva otvora koji vode do jezgre, naznačen time što obloga je erodibilna u prethodno određenim uvjetima pH. Patent sadrži još 21 patentni zahtjev.
Claims (22)
1. Oralni oblik doziranja s erodibilnom jezgrom koja sadrži 5-[4-[2-(N-metil-N-(2-piridil)amino)etoksi]benzil] tiazolidin-2,4-dion, ili njegovu farmaceutski prihvatljivu sol ili solvat, i metformin, ili njegovu farmaceutski prihvatljivu sol ili solvat, gdje navedena jezgra nosi oblogu s jednim ili dva otvora koji vode do jezgre, naznačen time što obloga je erodibilna u prethodno određenim uvjetima pH.
2. Oralni oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time što sadrži
(i) erodibilnu jezgru, gdje navedena erodibilna jezgra sadrži 5-[4-[2-(N-metil-N-(2-piridil)amino)etoksi] benzil]tiazolidin-2,4-dion, ili njegovu farmaceutski prihvatljivu sol ili solvat, i metformin, ili njegovu farmaceutski prihvatljivu sol ili solvat; i
(ii) erodibilnu oblogu oko navedene jezgre, gdje navedena obloga sadrži jedan ili dva otvora koji se uglavnom potpuno pružaju kroz navedenu oblogu do navedene jezgre, no uglavnom ne prodiru u navedenu jezgru, te omogućuju komunikaciju između radnog medija i navedene jezgre;
gdje se 5-[4-[2-(N-metil-N-(2-piridil)amino)etoksi]benzil]tiazolidin-2,4-dion, ili njegovu farmaceutski prihvatljivu sol ili solvat, i metformin, ili njegovu farmaceutski prihvatljivu sol ili solvat, iz erodibilne jezgre uglavnom otpušta kroz navedeni otvor ili navedene otvore, te kod erodiranja navedene erodibilne obloge u prethodno određenim uvjetima pH.
3. Oralni oblik doziranja u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što erodibilna obloga je enterička obloga.
4. Oralni oblik doziranja u skladu s patentnim zahtjevom 3, naznačen time što enterička obloga nije propusna.
5. Oralni oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time što erodibilna jezgra je tako formulirana da omogući neposredno otpuštanje i 5-[4-[2-(N-metil-N-(2-piridil)amino)etoksi]benzil] tiazolidin-2,4-diona, ili njegove farmaceutski prihvatljive soli ili solvata, i metformina, ili njegove farmaceutski prihvatljive soli ili solvata.
6. Oralni oblik doziranja u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni oblik doziranja je tabletni oblik doziranja.
7. Oralni oblik doziranja u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što erodibilna obloga erodira kod raspona pH od 4,5 do 8.
8. Oralni oblik doziranja u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što erodibilna obloga erodira kod raspona pH od 5 do 7.
9. Oralni oblik doziranja u skladu s patentnim zahtjevom 7 ili 8, naznačen time što materijal kojeg se upotrebljava za erodibilnu oblogu se bira između polimetakrilatnih polimera, suobrađenih polivinil-acetat-ftalatnih, celuloza-acetat-trimelitatnih, celulozna-acetat-ftalatnih, hidroksipropilmetilceluloza-ftalatnih polimera i njihovih kopolimera.
10. Oralni oblik doziranja u skladu s patentnim zahtjevom 9, naznačen time što navedeni materijal se bira između celuloza-acetat-trimelitata, polivinil-acetat-ftalata, hidroksipropilmetilceluloza-ftalata 55, Acryl-eze™, Aquateric™, celulozna-acetat-ftalata, Eudragit™ L30D, Eudragit™ L, Eudragit™ S i šelak.
11. Oralni oblik doziranja u skladu s patentnim zahtjevom 10, naznačen time što navedeni materijal je Eudragit™ L30D.
12. Oralni oblik doziranja u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sadrži 2 do 12 mg 5-[4-[2-(N-metil-N-(2-piridil)amino)etoksi]benzil]tiazolidin-2,4-diona.
13. Oralni oblik doziranja u skladu s patentnim zahtjevom 12, naznačen time što sadrži 4 do 8 mg 5-[4-[2-(N-metil-N-(2-piridil)amino)etoksi]benzil]tiazolidin-2,4-diona.
14. Oralni oblik doziranja u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sadrži 100 do 3000 mg metformina.
15. Oralni oblik doziranja u skladu s patentnim zahtjevom 14, naznačen time što sadrži 500 do 1000 mg metformina.
16. Oralni oblik doziranja u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što 5-[4-[2-(N-metil-N-(2-piridil)amino)etoksi]benzil]tiazolidin-2,4-dion je u obliku maleatne soli.
17. Oralni oblik doziranja u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što metformin je u obliku hidrokloridne soli.
18. Oralni oblik doziranja u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što tipične veličine navedenog ili navedenih otvora, koje treba načiniti u oblozi, kada su kružni imaju raspon promjera od 0,5-0,8 mm.
19. Oralni oblik doziranja u skladu s bilo kojim od patentnih zahtjeva 1 do 17, naznačen time što površine otvora koji nisu kružni su u rasponu od 0,19 do 50,3 mm2.
20. Oralni oblik doziranja u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što erodibilna obloga oko navedene jezgre sadrži dva otvora koji se uglavnom potpuno pružaju kroz navedenu oblogu do navedene jezgre, no uglavnom ne prodiru u navedenu jezgru, te omogućuju komunikaciju između radnog medija i navedene jezgre.
21. Oralni oblik doziranja u skladu s patentnim zahtjevom 20, naznačen time što otvori u erodibilnoj oblozi se nalaze na nasuprotnim stranama.
22. Postupak priprave oralnog oblika doziranja u skladu s patentnim zahtjevom 1, naznačen time što navedeni postupak se sastoji u:
(a) pripravi erodibilne tabletne jezgre koja sadrži 5-[4-[2-(N-metil-N-(2-piridil)amino)etoksi]benzil] tiazolidin-2,4-dion, ili njegovu farmaceutski prihvatljivu sol ili solvat, i metformin, ili njegovu farmaceutski prihvatljivu sol ili solvat,
(b) oblaganju jezgre materijalom čija erodibilnost ovisi o pH, te
(c) pravljenju jednog ili dva otvora u oblozi.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0318824.0A GB0318824D0 (en) | 2003-08-11 | 2003-08-11 | Novel composition |
PCT/EP2004/008970 WO2005013956A1 (en) | 2003-08-11 | 2004-08-09 | Novel composition comprising rosiglitazone and another antidiabetic agent |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100160T1 true HRP20100160T1 (hr) | 2010-05-31 |
Family
ID=27840010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100160T HRP20100160T1 (hr) | 2003-08-11 | 2010-03-18 | Pripravak koji sadrži roziglitazon i metformin |
Country Status (37)
Country | Link |
---|---|
US (1) | US20080206336A1 (hr) |
EP (1) | EP1663191B1 (hr) |
JP (1) | JP4714147B2 (hr) |
KR (1) | KR20060071396A (hr) |
CN (2) | CN102397551A (hr) |
AP (1) | AP2006003489A0 (hr) |
AR (1) | AR045230A1 (hr) |
AT (1) | ATE455542T1 (hr) |
AU (1) | AU2004262933B2 (hr) |
BR (1) | BRPI0413419A (hr) |
CA (1) | CA2534480A1 (hr) |
CY (1) | CY1109923T1 (hr) |
DE (1) | DE602004025257D1 (hr) |
DK (1) | DK1663191T3 (hr) |
EA (2) | EA200800966A1 (hr) |
EC (1) | ECSP066338A (hr) |
ES (1) | ES2339554T3 (hr) |
GB (1) | GB0318824D0 (hr) |
HK (1) | HK1092051A1 (hr) |
HR (1) | HRP20100160T1 (hr) |
IL (1) | IL173177A0 (hr) |
IS (1) | IS2745B (hr) |
MA (1) | MA27996A1 (hr) |
MX (1) | MXPA06001629A (hr) |
MY (1) | MY151053A (hr) |
NO (1) | NO20061161L (hr) |
NZ (1) | NZ544632A (hr) |
OA (1) | OA13233A (hr) |
PE (1) | PE20050357A1 (hr) |
PL (1) | PL1663191T3 (hr) |
PT (1) | PT1663191E (hr) |
SG (1) | SG165178A1 (hr) |
SI (1) | SI1663191T1 (hr) |
TW (1) | TW200517146A (hr) |
UA (1) | UA82537C2 (hr) |
UY (1) | UY28461A1 (hr) |
WO (1) | WO2005013956A1 (hr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR030920A1 (es) * | 1999-11-16 | 2003-09-03 | Smithkline Beecham Plc | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones |
GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
EP1686967A4 (en) * | 2003-11-25 | 2012-08-08 | Smithkline Beecham Cork Ltd | CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES |
US20100323015A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
WO2010009433A1 (en) * | 2008-07-18 | 2010-01-21 | Valeant Pharmaceuticals International | Modified release formulation and methods of use |
US20100323016A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
WO2011161521A1 (en) * | 2010-06-21 | 2011-12-29 | Lupin Limited | Compositions comprising metformin and rosiglitazone |
EP2590634B1 (en) * | 2010-07-09 | 2016-03-09 | BHV Pharma, Inc. | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin |
CN102727459A (zh) * | 2011-04-15 | 2012-10-17 | 江苏豪森医药集团有限公司 | 一种具有第一和第二活性药物的制剂 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
US5952509A (en) * | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
GB9619757D0 (en) * | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
US20010049380A1 (en) * | 1997-06-18 | 2001-12-06 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and sulphonylurea |
US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
US20020006939A1 (en) * | 1997-10-13 | 2002-01-17 | Smithkline Beecham P.L.C. | Use of thiazolidinediones for the treatment of hyperglycaemia |
JP4533531B2 (ja) * | 1998-04-03 | 2010-09-01 | ビーエム リサーチ エイ/エス | 制御放出組成物 |
US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
UA67802C2 (uk) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
DE69833179T2 (de) * | 1998-11-10 | 2006-09-07 | The Procter & Gamble Company, Cincinnati | Bleichmittelzusammensetzungen |
US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
IL143002A0 (en) * | 1998-11-12 | 2002-04-21 | Smithkline Beecham Plc | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
EP1231917A2 (en) * | 1999-11-16 | 2002-08-21 | Smithkline Beecham Plc | Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
ATE367151T1 (de) * | 2000-05-01 | 2007-08-15 | Aeropharm Technology Llc | Kernformulierung |
GB0027471D0 (en) * | 2000-11-08 | 2000-12-27 | Smithkline Beecham Plc | Processes |
GB0120835D0 (en) * | 2001-08-28 | 2001-10-17 | Smithkline Beecham Plc | Process |
GB0127805D0 (en) * | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
MY139719A (en) * | 2002-02-12 | 2009-10-30 | Glaxo Group Ltd | Oral dosage form for controlled drug release |
GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
-
2003
- 2003-08-11 GB GBGB0318824.0A patent/GB0318824D0/en not_active Ceased
-
2004
- 2004-08-09 BR BRPI0413419-2A patent/BRPI0413419A/pt not_active IP Right Cessation
- 2004-08-09 UY UY28461A patent/UY28461A1/es not_active Application Discontinuation
- 2004-08-09 SG SG200901679-1A patent/SG165178A1/en unknown
- 2004-08-09 DK DK04741403.2T patent/DK1663191T3/da active
- 2004-08-09 EP EP04741403A patent/EP1663191B1/en active Active
- 2004-08-09 MY MYPI20043234 patent/MY151053A/en unknown
- 2004-08-09 OA OA1200600045A patent/OA13233A/en unknown
- 2004-08-09 TW TW093123804A patent/TW200517146A/zh unknown
- 2004-08-09 CA CA002534480A patent/CA2534480A1/en not_active Abandoned
- 2004-08-09 KR KR1020067002884A patent/KR20060071396A/ko not_active Application Discontinuation
- 2004-08-09 ES ES04741403T patent/ES2339554T3/es active Active
- 2004-08-09 CN CN2011103143770A patent/CN102397551A/zh active Pending
- 2004-08-09 AR ARP040102846A patent/AR045230A1/es not_active Application Discontinuation
- 2004-08-09 DE DE602004025257T patent/DE602004025257D1/de active Active
- 2004-08-09 AP AP2006003489A patent/AP2006003489A0/xx unknown
- 2004-08-09 EA EA200800966A patent/EA200800966A1/ru unknown
- 2004-08-09 WO PCT/EP2004/008970 patent/WO2005013956A1/en active Application Filing
- 2004-08-09 EA EA200600400A patent/EA011550B1/ru not_active IP Right Cessation
- 2004-08-09 AT AT04741403T patent/ATE455542T1/de active
- 2004-08-09 JP JP2006522974A patent/JP4714147B2/ja not_active Expired - Fee Related
- 2004-08-09 MX MXPA06001629A patent/MXPA06001629A/es active IP Right Grant
- 2004-08-09 US US10/567,803 patent/US20080206336A1/en not_active Abandoned
- 2004-08-09 PT PT04741403T patent/PT1663191E/pt unknown
- 2004-08-09 AU AU2004262933A patent/AU2004262933B2/en not_active Ceased
- 2004-08-09 PE PE2004000771A patent/PE20050357A1/es not_active Application Discontinuation
- 2004-08-09 NZ NZ544632A patent/NZ544632A/en not_active IP Right Cessation
- 2004-08-09 PL PL04741403T patent/PL1663191T3/pl unknown
- 2004-08-09 SI SI200431376T patent/SI1663191T1/sl unknown
- 2004-08-09 CN CN2004800232304A patent/CN1835741B/zh not_active Expired - Fee Related
- 2004-09-08 UA UAA200601353A patent/UA82537C2/uk unknown
-
2006
- 2006-01-16 IL IL173177A patent/IL173177A0/en unknown
- 2006-01-31 EC EC2006006338A patent/ECSP066338A/es unknown
- 2006-02-17 MA MA28817A patent/MA27996A1/fr unknown
- 2006-03-02 IS IS8337A patent/IS2745B/is unknown
- 2006-03-10 NO NO20061161A patent/NO20061161L/no not_active Application Discontinuation
- 2006-11-15 HK HK06112571.6A patent/HK1092051A1/xx not_active IP Right Cessation
-
2010
- 2010-03-18 HR HR20100160T patent/HRP20100160T1/hr unknown
- 2010-03-22 CY CY20101100261T patent/CY1109923T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100160T1 (hr) | Pripravak koji sadrži roziglitazon i metformin | |
HRP20010343B1 (hr) | Farmaceutski pripravak za modificirano otpuštanje senzitizatora za inzulin i drugog antidijabetičkog sredstva | |
DZ3316A1 (fr) | Sels de chlorhydrate de 5- 4- 2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione | |
MY129317A (en) | Taste masked pharmaceutical compositions | |
DK1246622T3 (da) | Nye substituerede benzimidazol dosisformer og metoder til deres anvendelse | |
DE69937650D1 (de) | Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe | |
DE60019116D1 (de) | Neue omeprazole und (s)-omeprazole zusammensetzung | |
EA200701680A1 (ru) | Лекарственная форма для перорального введения, содержащая розиглитазон | |
DE60004196D1 (de) | Polymorph von 5-[4-[2-(n-methyl-n-(2-pyrdyl)amino)äthoxy]benzyl]thiazolidin-2,4-dion, maleinsäuresalz | |
IL155036A0 (en) | Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] benzyl] thiazolidine-2,4-dione maleate and pharmaceutical compositions containing the same | |
NO20003069L (no) | 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl]tiazolidin- 2,4-dion-maleinsyre-salt-hydrat som farmasøytikum | |
HRP20010342B1 (hr) | Farmaceutski pripravak za modificirano otpuštanjesenzitizatora za inzulin | |
CY1105252T1 (el) | Το υδροχλωρικο αλας της 5-[4-[2-(ν-μεθυλο-ν-(2-πυριδυλο)αμινο)-αιθοξυ]βενζυλο]θειαζολιδινο-2,4-διονης | |
PE20050335A1 (es) | Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion | |
AR048948A1 (es) | Una composicion farmaceutica antimicobacteriana | |
LU90616B1 (fr) | Nouvelle forme cristalline du chlorhydrate de 6-hydroxy-3-(4-(2-(piperidin-1-YL)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophene | |
AR038417A1 (es) | Forma de dosificacion oral, procedimiento para prepararla y uso de una base debil farmaceuticamente aceptable o una sal o solvato farmaceuticamente aceptable de la misma para preparar dicha forma de dosificacion oral | |
LU90617B1 (fr) | Nouvelle forme cristalline du chlorhydrate de 6-hydroxy-3-(4-(2-(piperidin-1-Y1)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophene | |
MXPA05000303A (es) | Formulaciones farmaceuticas de liberacion controlada. | |
DK1446404T3 (da) | Rosiglitazonedisylater og deres anvendelse som antidiabetika | |
AP1785A (en) | Tartrate salt of thiazolidinedione derivative. | |
NO20031435L (no) | Natriumsalter av 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion | |
PL363683A1 (en) | 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical |